Systemic sclerosis-endothelial cell antiangiogenic pentraxin 3 and matrix metalloprotease 12 control human breast cancer tumor vascularization and development in mice

Neoplasia

Volumn 11, Issue 10, 2009, Pages 1106-1115

  Margheri, Francesca ^a   Serratì, Simona ^a   Lapucci, Andrea ^a   Chillà, Anastasia ^a   Giusti, Betti ^a   Pucci, Marco ^a   Torre, Eugenio ^a   Bianchini, Francesca ^a   Calorini, Lido ^a   Albini, Adriana ^b   Ventura, Agostina ^c   Fibbi, Gabriella ^a   Del Rosso, Mario ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b IRCCS MULTIMEDICA   (Italy)

^c CENTRO DI BIOTECNOLOGIE AVANZATE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOSTATIN; FIBROBLAST GROWTH FACTOR 2; MACROPHAGE ELASTASE; PENTRAXIN 3; PLASMINOGEN ACTIVATOR;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CELL INVASION; CLINICAL ARTICLE; CONTROLLED STUDY; GENETIC TRANSFECTION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SYSTEMIC SCLEROSIS; TUMOR GROWTH; TUMOR NECROSIS; TUMOR VASCULARIZATION;

EID: 70249135679     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.09934     Document Type: Article

References (25)

1. Wittekind C and Neid M (2005). Cancer invasion and metastasis. Oncology 69, 14-16.
2. Carmeliet P and Collen D (2000). Transgenic mouse models in angiogenesis and cardiovascular disease. J Pathol 190, 387-405. (Pubitemid 30141384)
3. Ferrara N (2000). VEGF: an update on biological and therapeutic aspects. Curr Opin Biotechnol 11, 617-624.
4. Maxwell PH (2005). The HIF pathway in cancer (2005). Semin Cell Dev Biol 16, 523-530.
5. Cutolo M, Grassi W, and Matucci-Cerinic M (2003). Raynaud's phenomenon and the role of capillaroscopy. Arthritis Rheum 48, 3023-3030.
6. LeRoy EC (1996). Systemic sclerosis: a vascular perspective. Rheum Dis Clin North Am 22, 675-694.
7. Distler O, Distler JH, Scheid A, Acker T, Hirth A, Rethage J,Michel BA, Gay RE, Muller-Ladner U, Matucci-Cerinic M, et al. (2004). Uncontrolled expression of vascular endothelial growth factor and its receptors leads to insufficient skin angiogenesis in patients with systemic sclerosis. Circ Res 95, 109-116. (Pubitemid 38931842)
8. Kuwana M, Okazaki Y, Yasuoka H, Kawakami Y, and Ikeda Y (2004). Defective vasculogenesis in systemic sclerosis. Lancet 364, 603-610.
9. D'Alessio S, Fibbi G, Cinelli M, Guiducci S, Del Rosso A, Margheri F, Serrati S, Pucci M, Kahaleh B, Fan P, et al. (2004). Matrix metalloproteinase 12-dependent cleavage of urokinase receptor in systemic sclerosis microvascular endothelial cells results in impaired angiogenesis. Arthritis Rheum 50, 3275-3285. (Pubitemid 39372005)
10. Margheri F,Manetti M, Serratì S,Nosi D, Pucci M,Matucci-Cerinic M, Kahaleh B, Bazzichi L, Fibbi G, Ibba-Manneschi L, et al. (2006). Domain 1 of the urokinasetype plasminogen activator receptor is required for its morphologic and functional, β2 integrin-mediated connection with actin cytoskeleton in human microvascular endothelial cells: failure of association in systemic sclerosis endothelial cells. Arthritis Rheum 54, 3926-3938. (Pubitemid 44955896)
11. Giusti B, Fibbi G, Margheri F, Serratì S, Rossi L, Poggi F, Lapini I, Magi A, Del Rosso A, Cinelli M, et al. (2006). A model of anti-angiogenesis: differential transcriptosome profiling of microvascular endothelial cells from diffuse systemic sclerosis patients. Arthritis Res Ther 8 (4), R115.
12. Presta M, Camozzi M, Salvatori G, and Rusnati M (2007). Role of the soluble pattern recognition receptor PTX3 in vascular biology. J Cell Mol Med 11, 723-738. (Pubitemid 47313297)
13. Rusnati M, Camozzi M, Moroni E, Bottazzi B, Peri G, Indraccolo S, Amadori A, Mantovani A, and Presta M (2004). Selective recognition of fibroblast growth factor-2 by the long pentraxin PTX3 inhibits angiogenesis. Blood 104, 92-99. (Pubitemid 38879843)
14. Serratì S, Margheri F, Fibbi G, Di Cara G, Minafra L, Pucci-Minafra I, Lotta F, Annunziato F, Pucci M, and Del Rosso M (2008). Endothelial cells and normal breast epithelial cells enhance invasion of breast carcinoma cells by CXCR-4- dependent up-regulation of urokinase-type plasminogen activator receptor (uPAR, CD87) expression. J Pathol 214, 545-554.
15. Margheri F, D'Alessio S, Serratí S, Pucci M, Annunziato F, Cosmi L, Liotta F, Angeli R, Angelucci A, Gravina GL, et al. (2005). Effects of blocking urokinase receptor signaling by antisense oligonucleotides in a mouse model of experimental prostate cancer bone metastases. Gene Ther 12, 702-714. (Pubitemid 40575610)
16. Stathakis P, Fitzgerald M, Matthias LJ, Chesterman CN, and Hogg PJ (1997). Generation of angiostatin by reduction and proteolysis of plasmin. J BiolChem272, 29641-29645.
17. Gorrin-Rivas MJ, Arii S, Furutani S, Mizumoto M, Mori A, Hanaki K,Maeda M, Furuyama H, Kondo Y, and Imamura M (2000). Mouse macrophage metalloelastase gene transfer into a murine melanoma suppresses primary tumor growth by halting angiogenesis. Clin Cancer Res 6, 1647-1654. (Pubitemid 30305056)
18. Kugler MC, Wei Y, and Chapman HA (2003). Urokinase receptor and integrin interactions. Curr Pharm Des 9, 1565-1574.
19. Binder BR, Mihaly J, and Prager GW (2007). uPAR-uPA-PAI-1 interactions and signaling: a vascular biologist's view. Thromb Haemost 97, 336-342. (Pubitemid 46437793)
20. Madsen CD and Sidenius N (2008). The interaction between urokinase receptor and vitronectin in cell adhesion and signalling. Eur J Cell Biol 87, 617-629.
21. Gately S, Twardowski P, Stack MS, Patrick M, Boggio L, Cundiff DL, Schnaper HW, Madison L, Volpert O, Bouck N, et al. (1996). Human prostate carcinoma cells express enzymatic activity that converts human plasminogen to the angiogenesis inhibitor, angiostatin. Cancer Res 56, 4887-4890. (Pubitemid 26374424)
22. Stathakis P, Fitzgerald M, Matthias LJ, Chesterman CN, and Hogg PJ (1997). Generation of angiostatin by reduction and proteolysis of plasmin. Catalysis by a plasmin reductase secreted by cultured cells. Biol Chem 272, 20641-20645.
23. Stathakis P, Lay AJ, Fitzgerald M, Schlieker C, Matthias LJ, and Hogg PJ (1999). Angiostatin formation involves disulfide bond reduction and proteolysis in kringle 5 of plasmin. J Biol Chem 274, 8910-8916. (Pubitemid 29164692)
24. Billottet C, Janji B, Thuery JP, and Jouanneau J (2002). Rapid tumor development and potent vescularization are independent events in carcinoma producing FGF-1 or FGF-2. Oncogene 21, 8128-8139. (Pubitemid 35454415)
25. Cavallaro U, Wu Z, Di Palo A, Montesano R, Pepper MS, Maier JA, and Soria MR (1998). FGF-2 stimulates migration of Kaposi's sarcoma-like vascular cells by HGF-dependent relocalization of the urokinase receptor. FASEB J 12, 1027-1034. (Pubitemid 28359584)